Sotyktu (Deucravacitinib): A New Oral Treatment for Moderate to Severe Plaque Psoriasis

Understanding Psoriasis and the Emergence of Sotyktu

Psoriasis is a chronic autoimmune condition that affects millions worldwide, presenting as scaling on the skin's surface. It's characterized by symptoms such as itchiness, darkened or red skin patches, soreness, and sometimes swollen, painful joints. In India, while specific prevalence data for psoriasis can vary, it is a recognized and significant dermatological concern. The condition can impact not only physical well-being but also emotional and social aspects of life.

For individuals living with moderate to severe plaque psoriasis, finding effective and manageable treatment options has been a long-standing challenge. Historically, treatments have included topical therapies, phototherapy, and systemic medications. Systemic medications, while often effective, can come with significant side effects and may require injections or administration in a clinical setting. This is where the recent approval of deucravacitinib, marketed as Sotyktu, marks a significant advancement in the treatment landscape.

In September 2022, the U.S. Food and Drug Administration (FDA) approved deucravacitinib (Sotyktu) for the treatment of adults with moderate to severe plaque psoriasis. This approval offers a new hope for many, providing an oral medication that targets the underlying immune response driving psoriasis, with a potentially more favorable side effect profile compared to some older systemic treatments.

What is Sotyktu (Deucravacitinib)?

Sotyktu is a groundbreaking oral medication that belongs to a class of drugs known as tyrosine kinase 2 (TYK2) inhibitors. Unlike many other systemic psoriasis treatments that require injections, Sotyktu is taken as a once-daily tablet. This makes it a convenient and accessible option for many patients.

How Does Sotyktu Work?

The effectiveness of Sotyktu lies in its targeted mechanism of action. It works by selectively inhibiting TYK2, a protein that plays a crucial role in the immune system's inflammatory pathways. In psoriasis, an overactive immune system leads to inflammation and the rapid growth of skin cells, resulting in the characteristic plaques. By blocking TYK2, Sotyktu helps to dampen this inflammatory response, thereby reducing the severity of psoriasis symptoms.

This selective inhibition is key. TYK2 is part of a signaling pathway that is involved in various immune responses. By targeting TYK2 specifically, Sotyktu aims to modulate the immune system effectively while potentially minimizing broader immunosuppression that can be associated with other systemic treatments.

Clinical Trial Results: Efficacy and Safety

The FDA's approval of Sotyktu was based on robust clinical trial data, including two major studies that compared deucravacitinib to a placebo and another existing oral treatment, apremilast.

Key Findings from Clinical Trials:

• Superior Efficacy: In the clinical trials, a significant percentage of participants treated with deucravacitinib achieved substantial skin clearance. At week 16, approximately 54% of patients on deucravacitinib achieved clear or almost clear skin, compared to about 32% of those on apremilast.
• Sustained Improvement: The positive effects were sustained over time. By week 24, around 59% of deucravacitinib users showed clear or nearly clear skin, a result that was significantly better than the 31% seen with apremilast.
• Long-Term Potential: Preliminary data suggests that deucravacitinib remains effective for up to two years with continuous treatment, although further long-term studies are ongoing to fully understand its durability.
• Favorable Side Effect Profile: The medication was generally well-tolerated by most participants. While all medications have potential side effects, clinical trials indicated that deucravacitinib had fewer adverse effects compared to some older oral psoriasis medications.

Who is Sotyktu For?

Sotyktu is currently approved for adults with moderate to severe plaque psoriasis. Doctors may consider prescribing Sotyktu for patients who:

• Are candidates for systemic therapy, meaning their psoriasis is severe enough to warrant treatment beyond topical creams or light therapy.
• Prefer an oral medication over injections.
• Are seeking a treatment option with a potentially improved side effect profile compared to older systemic therapies.

It's important to note that Sotyktu is currently available only as the brand-name medication Sotyktu. A generic version is not yet available.

Dosage and Administration

Sotyktu is available as a 6-milligram (mg) tablet. The recommended dosage is one tablet taken once daily. The medication can be taken with or without food, offering flexibility for patients.

Potential Side Effects and Precautions

While Sotyktu is considered generally safe and effective, like all medications, it can cause side effects. It's crucial for patients to be aware of these and discuss them with their doctor.

Common Side Effects:

The most common side effects observed in clinical trials include:

• Increased risk of infections: This is a significant consideration with any medication that modulates the immune system. Patients may have an increased chance of developing infections, including tuberculosis and the reactivation of dormant viruses like herpes zoster (shingles).
• Upper respiratory tract infections
• Headaches
• Diarrhea
• Nausea
• Fatigue

Serious Side Effects and Precautions:

While less common, some serious side effects can occur:

• Infections: Patients should be screened for tuberculosis before starting Sotyktu and monitored for signs of infection during treatment. Any signs of active infection should be reported to a doctor immediately.
• Malignancy: As with other immune-modulating therapies, there is a potential increased risk of certain cancers.
• Thrombotic Events: Although rare, there have been reports of blood clots.
• Liver Enzyme Elevations: Regular monitoring of liver function may be necessary.

Specific Populations:

• Pregnancy and Breastfeeding: The safety of Sotyktu during pregnancy and breastfeeding is not yet fully established. Women who are pregnant, plan to become pregnant, or are breastfeeding should discuss this with their doctor before starting treatment.
• Pediatric Use: Sotyktu is currently approved for adults and is not yet recommended for use in children.
• Allergies: Individuals who are allergic to deucravacitinib or any of the inactive ingredients in Sotyktu should not use this medication.

It is essential to have a thorough discussion with your healthcare provider about your medical history, including any existing infections, immune system issues, or other health conditions, before starting Sotyktu.

When to Consult a Doctor

It is important to consult with a doctor if you are experiencing symptoms of moderate to severe plaque psoriasis. A dermatologist can accurately diagnose your condition and discuss the most appropriate treatment options for you.

You should also consult your doctor if:

• You are considering starting Sotyktu or any new psoriasis medication.
• You experience any new or worsening symptoms of infection while taking Sotyktu.
• You have any concerns about potential side effects or the long-term effects of the medication.
• You become pregnant or plan to become pregnant while on treatment.

Living with Psoriasis: A Holistic Approach

While Sotyktu offers a significant advancement in managing moderate to severe plaque psoriasis, a holistic approach to living with the condition is crucial. This includes:

• Adhering to Treatment: Taking your medication as prescribed by your doctor is paramount for achieving the best results.
• Skin Care: Maintaining a good skincare routine, including moisturizing regularly, can help manage dryness and itching.
• Lifestyle Modifications: A healthy diet, regular exercise, stress management techniques (like yoga or meditation), and adequate sleep can contribute to overall well-being and may help manage psoriasis symptoms.
• Emotional Support: Living with a chronic condition can be challenging. Seeking support from family, friends, or support groups can be beneficial.

Psoriasis is a complex condition, but with advancements like Sotyktu and a comprehensive approach to care, individuals can achieve better control over their symptoms and improve their quality of life.

Additional Medical Guidance

This section adds practical context and preventive advice to help readers make informed healthcare decisions. It is important to verify symptoms early, consult qualified doctors, and avoid self-medication for persistent health issues.

Maintaining healthy routines, following prescribed treatment plans, and attending regular checkups can improve outcomes. If symptoms worsen or red-flag signs appear, immediate medical evaluation is recommended.

Quick Checklist

• Track symptoms and duration.

• Follow diagnosis and treatment from a licensed practitioner.

• Review medication side effects with your doctor.

• Seek urgent care for severe warning signs.